概括
在早期症状性阿尔茨海默病 (AD) 中,多纳尼马布显著减缓了认知和功能衰退. 这种粉样蛋白向治疗在TRAILBLAZER-ALZ 2试验中显示出临床益处.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 神经退行性疾病 神经退行性疾病
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是粉样β斑块.
- 阿尔茨海默病的早期症状阶段涉及轻度认知障碍或痴呆症.
- 开发有效的AD疾病修饰疗法仍然是一个关键的未满足的需求.
研究的目的:
- 为了评估donanemab的疗效和安全性,donanemab是一种针对N3pG相关的粉样β斑块的抗体,用于早期症状性AD.
- 评估donanemab对认知和功能衰退的影响.
- 为了分析大脑中粉样蛋白斑块的清除.
主要方法:
- TRAILBLAZER-ALZ 2试验是一项第三期,随机,双盲,安慰剂控制的研究.
- 患有早期症状AD的参与者接受了多纳米纳布或安慰剂的静脉注射.
- 认知和功能结果使用标准化天平进行评估,使用粉样蛋白PET成像测量斑块负担.
主要成果:
- 与安慰剂相比,多纳尼马布治疗导致认知和功能衰退的统计学显著减缓.
- 在多纳尼马布治疗的参与者中,很大一部分人实现了显著的粉样蛋白β斑块清除.
- 观察到不良事件,包括ARIA (粉样蛋白相关的成像异常).
结论:
- 多纳尼马布在减缓早期症状性阿尔茨海默病进展方面表现出有效性.
- 粉样蛋白斑块清除与临床益处相关.
- 需要进一步的研究和长期监测,才能充分了解donanemab的风险-益处概况.
相关概念视频
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113


